Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 4/20 | 0.86 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.86 |
| ▸ | HRH2 | P25021 | 2/20 | 0.86 |
| ▸ | HTR2A | P28223 | 2/20 | 0.86 |
| ▸ | DRD3 | P35462 | 2/20 | 0.86 |
| ▸ | HTR2B | P41595 | 2/20 | 0.86 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.86 |
| ▸ | USP2 | O75604 | 2/20 | 0.86 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.86 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.86 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.86 |
| ▸ | TEK | Q02763 | 1/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.62 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2058530 | 0.97 | HRH1 (0.82) | HRH1TDP1HRH2HTR2ADRD3 | |
| Hydrochloric Acid SCHEMBL10934197 | 0.96 | HRH1 (0.82) | HRH1TDP1HRH2HTR2ADRD3 | |
| SCHEMBL19390112 | 0.93 | HRH1 (0.79) | HRH1TDP1HRH2HTR2ADRD3 | |
| Cetirizine SCHEMBL2455487 | 0.93 | DRD3 (1.00) | HRH1TDP1HRH2HTR2ADRD3 | |
| Cetirizine SCHEMBL4176 | 0.93 | DRD3 (1.00) | HRH1TDP1HRH2HTR2ADRD3 | |
| SCHEMBL24022700 | 0.93 | HRH1 (0.79) | HRH1TDP1HRH2HTR2ADRD3 | |
| Levocetirizine SCHEMBL5935097 | 0.93 | DRD3 (1.00) | HRH1TDP1HRH2HTR2ADRD3 | |
| Levocetirizine SCHEMBL4914 | 0.93 | DRD3 (1.00) | HRH1TDP1HRH2HTR2ADRD3 | |
| Cetirizine SCHEMBL13724610 | 0.93 | DRD3 (1.00) | HRH1TDP1HRH2HTR2ADRD3 | |
| SCHEMBL2058738 | 0.93 | HRH1 (0.79) | HRH1TDP1HRH2HTR2ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1157016-B1 | A PROCESS FOR THE PREPARATION OF 2- 2- 4-(DIPHENYLMETHYL)-1-PIPERAZINYL]ETHOXY ACETIC ACID COMPOUNDS OR SALTS THEREOF | GEA FARMACEUTISK FABRIK AS (DK) | 2003-10-08 | — | — | EP | claimed |
| US-6469009-B1 | MIXTURE CONSISTING ESSENTIALLY OF PSEUDOEPHEDRINE AND COMPOUND SELECTED FROM 2-(4-(DIPHENYLMETHYL)-1-PIPERAZINYL)-ACETIC ACID OR AMIDE DERIVATIVES, THEIR INDIVIDUAL OPTICAL ISOMERS OR PHARMACEUTICALLY ACCEPTABLE SALTS | UCB, S.A. (BE) | 2002-10-22 | — | — | US | claimed |
| EP-1157016-A1 | A PROCESS FOR THE PREPARATION OF 2- 2- 4-(DIPHENYLMETHYL)-1-PIPERAZINYL]ETHOXY ACETIC ACID COMPOUNDS OR SALTS THEREOF | A/S GEA Farmaceutisk Fabrik (DK) | 2001-11-28 | — | — | EP | claimed |
| US-20010020023-A1 | Pharmaceutical compositions for the treatment of rhinitis | UCB PHARMA, S.A. (BE) | 2001-09-06 | — | — | US | claimed |
| WO-2000052000-A1 | A PROCESS FOR THE PREPARATION OF 2-{2-[4-(DIPHENYLMETHYL)-1-PIPERAZINYL]ETHOXY}ACETIC ACID COMPOUNDS OR SALTS THEREOF | A/S GEA FARMACEUTISK FABRIK (DK) | 2000-09-08 | — | — | WO | claimed |
| US-4525358-A | ANTIHISTAMINES, ANTIALLERGENS, ANTISPASMODICS, BRONCHODILATORS | UCB PHARMACEUTICALS, INC. (US) | 1985-06-25 | — | — | US | claimed |
| EP-0058146-B1 | 2-(4-(DIPHENYLMETHYL)-1-PIPERAZINYL)-ACETIC ACIDS AND THEIR AMIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | U C B, S.A. (BE) | 1984-06-27 | — | — | EP | claimed |
| US-8350031-B2 | Processes for the synthesis of levocetirizine and intermediates for use therein | CIPLA LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| US-8350031-B2 | Processes for the synthesis of levocetirizine and intermediates for use therein | CIPLA LIMITED (IN) | 2013-01-08 | — | — | US | disclosed |
| US-20110230496-A1 | NOVEL PROCESS FOR PREPARING HIGHLY PURE LEVOCETIRIZINE AND SALTS THEREOF | CHEMAGIS LTD. (IL) | 2011-09-22 | — | — | US | disclosed |
| US-20110230496-A1 | NOVEL PROCESS FOR PREPARING HIGHLY PURE LEVOCETIRIZINE AND SALTS THEREOF | CHEMAGIS LTD. (IL) | 2011-09-22 | — | — | US | disclosed |
| US-20110184174-A1 | Processes for the Synthesis of Levocetirizine and Intermediates for Use Therein | CIPLA LIMITED (IN) | 2011-07-28 | — | — | US | disclosed |
| US-20110184174-A1 | Processes for the Synthesis of Levocetirizine and Intermediates for Use Therein | CIPLA LIMITED (IN) | 2011-07-28 | — | — | US | disclosed |
| US-20010020023-A1 | Pharmaceutical compositions for the treatment of rhinitis | UCB PHARMA, S.A. (BE) | 2001-09-06 | — | — | US | disclosed |
| WO-2000052000-A1 | A PROCESS FOR THE PREPARATION OF 2-{2-[4-(DIPHENYLMETHYL)-1-PIPERAZINYL]ETHOXY}ACETIC ACID COMPOUNDS OR SALTS THEREOF | A/S GEA FARMACEUTISK FABRIK (DK) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000052000-A1 | A PROCESS FOR THE PREPARATION OF 2-{2-[4-(DIPHENYLMETHYL)-1-PIPERAZINYL]ETHOXY}ACETIC ACID COMPOUNDS OR SALTS THEREOF | A/S GEA FARMACEUTISK FABRIK (DK) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000052000-A1 | A PROCESS FOR THE PREPARATION OF 2-{2-[4-(DIPHENYLMETHYL)-1-PIPERAZINYL]ETHOXY}ACETIC ACID COMPOUNDS OR SALTS THEREOF | A/S GEA FARMACEUTISK FABRIK (DK) | 2000-09-08 | — | — | WO | disclosed |
| US-5538973-A | ANTIHISTAMINE, THROMBOXANE A2 ANTAGONIST | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1996-07-23 | — | — | US | disclosed |
| EP-0597112-A1 | NOVEL IMIDAZOLE DERIVATIVE, PHARMACEUTICAL USE THEREOF, AND INTERMEDIATE THEREFOR | Kyoto Pharmaceutical Industries, Ltd. (JP) | 1994-05-18 | — | — | EP | disclosed |
| US-4525358-A | ANTIHISTAMINES, ANTIALLERGENS, ANTISPASMODICS, BRONCHODILATORS | UCB PHARMACEUTICALS, INC. (US) | 1985-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184174-A1 | Processes for the Synthesis of Levocetirizine and Intermediates for Use Therein | CYP3A5, CYP4A11, IL5 | HRH1 82/4885TDP1 3275/4885HRH2 148/4885 |
| US-20010020023-A1 | Pharmaceutical compositions for the treatment of rhinitis | HRH4, HRH2, HRH1 | HRH1 3/4885TDP1 4206/4885HRH2 2/4885 |
| US-20110230496-A1 | NOVEL PROCESS FOR PREPARING HIGHLY PURE LEVOCETIRIZINE AND SALTS THEREOF | CYP51A1, TSLP, NR5A1 | HRH1 33/4885TDP1 2831/4885HRH2 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.